Checkpoint Therapeutics to Feature at Investment Conference
![Checkpoint Therapeutics to Feature at Investment Conference](https://investorshangout.com/images/blog/ihnews-Checkpoint%20Therapeutics%20to%20Feature%20at%20Investment%20Conference.jpg)
Checkpoint Therapeutics to Feature at H.C. Wainwright Conference
Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a notable player in the field of clinical-stage immunotherapy and targeted oncology, has announced an exciting opportunity for engagement at the renowned H.C. Wainwright 26th Annual Global Investment Conference. James Oliviero, the company's President and Chief Executive Officer, will be presenting a corporate overview, showcasing Checkpoint's mission and innovative treatments for solid tumor cancers.
Details of the Presentation
The conference is set to take place on an upcoming Tuesday, where attendees can tune in for the presentation scheduled at 10:00 a.m. ET. Participants will also have the chance to engage in in-person and virtual one-on-one meetings, facilitating direct interaction with the leadership of Checkpoint. This presents an excellent opportunity for investors to learn more about the company's strategic initiatives and product developments.
Accessing the Webcast
A webcast of the presentation will be conveniently accessible on Checkpoint’s News & Events page, categorized under the Investors section of their official website. This webcast will remain available for approximately 30 days post-presentation, allowing broader access for interested parties, especially those who may not be able to attend live.
About Checkpoint Therapeutics
Founded and headquartered in Waltham, Massachusetts, Checkpoint is focused on pioneering the acquisition, development, and commercialization of groundbreaking therapies targeting complex solid tumors. The company is enthusiastic about its flagship antibody product candidate, cosibelimab, a potentially differentiated anti-PD-L1 antibody licensed from the esteemed Dana-Farber Cancer Institute. This candidate is being assessed for its efficacy as a new treatment option for patients grappling with specific recurrent or metastatic cancers, notably including metastatic and locally advanced cutaneous squamous cell carcinoma (cSCC).
Innovative Drug Development
Moreover, Checkpoint continues to evaluate olafertinib, its leading small-molecule, and targeted anti-cancer agent identified as a third-generation epidermal growth factor receptor (EGFR) inhibitor. This agent is being studied for its potential as an innovative treatment for patients suffering from EGFR mutation-positive non-small cell lung cancer. Such advancements exemplify Checkpoint's unwavering commitment to enhancing patient outcomes through targeted therapies.
Company Contact Information
For further inquiries, the company’s Media Relations can be contacted via:
Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com
Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
arr@lifesciadvisors.com
Frequently Asked Questions
What is Checkpoint Therapeutics known for?
Checkpoint Therapeutics is known for its clinical-stage immunotherapy and targeted oncology, focusing on innovative treatments for solid tumors.
Who is presenting at the H.C. Wainwright conference?
James Oliviero, the President and CEO of Checkpoint Therapeutics, will present an overview of the company.
When is the H.C. Wainwright conference?
The conference is set for an upcoming date, with Checkpoint’s presentation scheduled for 10:00 a.m. ET.
How can I access the presentation webcast?
The webcast will be available on the Investors section of Checkpoint’s website for 30 days after the conference.
What innovative drugs is Checkpoint developing?
Checkpoint is evaluating cosibelimab and olafertinib as potential treatments for specific cancers, highlighting its commitment to advancing oncology care.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Rising Bankruptcy Filings in Commercial Sector Highlight Trends
- Metabolomics Technologies Market Set to Surge by 2034
- Brunswick Corporation Awarded Trustworthy Company Recognition
- Prepare for Safety: Michigan Church Security Conference 2024
- Myosin's Innovative Marketing Platform Redefines Advertising Impact
- Goya Foods Launches GOYA® Cares Hydrate for Hope Campaign
- Acer Introduces Eco-Friendly Vero PD2 Series LED Projectors
- Tower Arch Capital Partners with ACS Manufacturing for Growth
- Winking Studios Unveils GenMotion.AI for 3D Animation Innovation
- Norfolk Southern Signs Tentative Agreements with SMART-TD Unions
- Wells Fargo Advises Investors to Buy Election Weakness
- Tech Stocks Struggle Amid Economic Growth Concerns
- Blue Circle Health Launches New T1D Program in Northern States
- West Shore Home Appoints Al Patel as New Chief Marketing Officer
- Digestion Resistant Maltodextrin Market Set for Remarkable Growth
- Mid-Atlantic BioTherapeutics and Accelero Unite for Drug Discovery
- Peptide Therapeutics Market to Reach USD 85.9 Billion by 2031
- Saphyre and WTax Launch Innovative Tax Reclaim Solutions
- Steve Varsano Receives Aviator Award for Lifetime Achievement
- Volaris Announces August 2024 Traffic Outcomes: 87% Load Factor
- Sanguine Biosciences Achieves ISO Certifications for Quality
- Kuehn Law Investigates Mergers of FBMS, IP, AFBI, CNDA Stocks
- House Doctors Launches Aging in Place Services Nationwide
- Alibaba International Concludes 2024 E-Commerce Challenge
- Biden Administration Lacks Business Experience, New Study Reveals
Recent Articles
- SkyQuest Reveals Growth in IoT Node and Gateway Market
- Industrial Lubricants Market Growth to USD 68.42 Billion Soon
- Edible Garden Expands Organic Herb Offerings in New Jersey
- Survey Highlights Employee Relations as Business Complexity Factor
- GUESS Watches Marks 40 Years of Trendsetting Innovation
- GRI Bio to Showcase Innovative Therapies at European Congress
- Cinnamon's Role in Wound Care: A Natural Deodorizing Solution
- HP Overtakes Apple in Laptop Sales During Q1 of 2024
- Honda Launches Funding Cycle for Community Organizations
- Stacy Moscow Takes the Helm as Chief Transformation Officer
- MARA Reports August Mining Updates and Bitcoin Production
- Egret Therapeutics Appoints Dr. Ron Cohen to Board of Directors
- ROCKWOOL A/S Announces Share Buyback Program Updates
- Aqua-Tots Swim School Launches First Location in New York
- HydroGraph Files New Patents for Advanced Graphene Technology
- Ciena Corp Reports Impressive Q3 Earnings and Revenue Growth
- Waterdrop Inc. Reports Record Q2 Growth and Special Dividend
- Mobilicom Launches Innovative 8-Inch Ground Control Station
- Innovative Food Holdings Closes Deal for igourmet.com Business
- Invivyd Begins Phase 1 Trial for VYD2311 to Combat COVID-19
- DICK'S Sporting Goods Expands Growth Outlook After Q2 Success
- Revolutionizing Men's Health: Huddle's Innovative Approach
- Top Stock Picks for Investors: Insights into Key Companies
- Former Pennsylvania Attorney Faces Consequences for Tax Evasion
- Navigating Recent US Equity Market Changes and Opportunities